[Long-term course of hypertrophic cardiomyopathy: drug versus surgical therapy].
139 patients with hypertrophic cardiomyopathy (HCM) have been followed up for 1-28 years (mean 8.9 years). Group 1 consisted of 60 patients (mean age 38 years) without indication for septal myectomy (SM) (no pressure gradient at rest in 8, pressure gradient less than 50 mm Hg in 52 cases); group 2 consisted of 79 patients (mean age 36 years) who had SM (pressure gradient at rest 70 mm Hg). Management in group 1 was the following: (1a) propranolol (n = 20) (160 mg/d), (1b) verapamil (n = 18) (360 mg/d) and (1c) no therapy (n = 22). 19 patients died in group 1 (mortality 3.6% year); 17 died in group 2 (mortality 2.4%/year). 10 year survival in group 1b was 80% and in groups 1a und 1c 67% and 65% respectively. Patients of group 1b had a higher survival rate (p less than 0.05) than the other subgroups. Surgery patients treated with verapamil (120-360 mg/d) (n = 17) had a 10-year survival rate of 100% compared to 78% for surgery patients (n = 34) without such treatment (p less than 0.05). In summary, it can be said that the overall survival rate after SM is better than that with medical treatment. Under verapamil, however, survival is not different from that after surgery. The most favorable outcome was observed in surgery patients under long-term therapy with verapamil, probably due to the reduction of systolic pressure overload (SM) and improvement in diastolic function (verapamil).
Seiler
C
C
Medizinische Poliklinik, Kardiologie, Universitätsspital Zürich.
Hess
O M
OM
Turina
J
J
Schoenbeck
M
M
Jenni
R
R
Rothlin
M
M
Senning
A
A
Turina
M
M
Krayenbühl
H P
HP
D000328:Adult; D002312:Cardiomyopathy, Hypertrophic / Q000401:mortality / Q000628:therapy*; D005260:Female; D006346:Heart Septum / Q000601:surgery*; D006801:Humans; D008137:Longitudinal Studies; D008297:Male; D011379:Prognosis; D011433:Propranolol / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use*
D011433:Propranolol; D014700:Verapamil
Langzeitverlauf der hypertrophen Kardiomyopathie: medikamentöse versus operative, Therapie.